October 30, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Nippon Organon Licenses Antidepressant to Meiji Seika Kaisha
 

Tokyo, Aug 5, 2004 (JCN) - Nippon Organon announced on August 3 that it has licensed Mirtazapine, its proprietary antidepressant, to Meiji Seika Kaisha (TSE: 2202).

Under the licensing agreement the two companies have signed, Meiji Seika Kaisha will be able to semi-exclusively develop and distribute Mirtazapine in Japan. Aiming to receive manufacturing approval, the two companies will jointly accelerate R&D for the antidepressant.

Currently, Mirtazapine is sold in over 60 countries under the trade name of "Remeron."

By Dale Hug Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Meiji Seika Kaisha Ltd. News  
  (Update) Meiji Dairies, Meiji Seika to Integrate Biz  (Sept 12, 2008)
  Meiji Seika Kaisha, Solvay Seiyaku Obtain Additional Approval for Fluvoxamine Maleate  (Oct 14, 2005)
  Meiji Seika Kaisha to Market New Antiaging Supplement  (Sept 16, 2005)
  Dainippon Pharmaceutical, Meiji Seika Kaisha Jointly Market New Formulations for Ebastel Antiallergic Agent  (July 11, 2005)
  Meiji Seika Kaisha Confirms Perilla-derived Rosmarinic Acid's Effectiveness Against Hay Fever  (Feb 28, 2005)
  Meiji Seika Kaisha Releases New Oral Cephem Antibiotic for Pediatric Use  (Aug 9, 2004)
  Nippon Organon Licenses Antidepressant to Meiji Seika Kaisha  (Aug 5, 2004)
  Meiji Seika to Introduce New PDT Drug for Early Lung Cancer Treatment  (June 25, 2004)
  Meiji Seika Subsidiary Receives Sales Approval for "MEIACT" in Spain  (Apr 27, 2004)
  Combination of Antioxidant Substance and Oligosaccharide May Prevent Lifestyle-related Diseases: Meiji Seika Kaisha  (Mar 30, 2004)



 Recent  Drugs & OTC News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Drugs & OTC news...

 Recent  Drugs & OTC News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)